Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review

Shionogi & Co Ltd (4507) - Financial and Strategic SWOT Analysis Review


- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for therapeutic areas including metabolic disorders, pain/central nervous system (CNS), infectious diseases and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd Key Recent Developments

Aug 28,2024: Shionogi to Announce Personnel Reassignment
Jul 29,2024: Shionogi & Co : Consolidated Financial Results for the First Quarter of Fiscal Year 2024 (IFRS)
Jul 11,2024: Shionogi : Notice of Head Office Relocation
Jul 08,2024: Domestic Launch of the In Vitro Diagnostic Pharmaceutical Shionogi MIC Dry Plate Cefiderocol

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note:Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Shionogi & Co Ltd - Key Facts
Shionogi & Co Ltd - Key Employees
Shionogi & Co Ltd - Key Employee Biographies
Shionogi & Co Ltd - Major Products and Services
Shionogi & Co Ltd - History
Shionogi & Co Ltd - Company Statement
Shionogi & Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Business Unit
Section 2 – Company Analysis
Company Overview
Shionogi & Co Ltd - Business Description
R&D Overview
Shionogi & Co Ltd - Corporate Strategy
Shionogi & Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Shionogi & Co Ltd - Strengths
Shionogi & Co Ltd - Weaknesses
Shionogi & Co Ltd - Opportunities
Shionogi & Co Ltd - Threats
Shionogi & Co Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Shionogi & Co Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 28, 2024: Shionogi to Announce Personnel Reassignment
Jul 29, 2024: Shionogi & Co : Consolidated Financial Results for the First Quarter of Fiscal Year 2024 (IFRS)
Jul 11, 2024: Shionogi : Notice of Head Office Relocation
Jul 08, 2024: Domestic Launch of the In Vitro Diagnostic Pharmaceutical Shionogi MIC Dry Plate Cefiderocol
Jul 01, 2024: Laboratory of International Wastewater-based Epidemiology Established at the school of Engineering, the University of Tokyo
Jun 03, 2024: Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
May 31, 2024: Position and Policy Regarding Reduction of the Investment Unit
May 30, 2024: Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections
May 13, 2024: Shionogi & Co : Consolidated Financial Results for Fiscal Year 2023 (IFRS)
Mar 04, 2024: Shionogi Announces the Initiation of the Second Phase of Comprehensive Cooperation in the Field of Infectious Diseases Focused on Malaria with Nagasaki University
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Shionogi & Co Ltd, Key Facts
Shionogi & Co Ltd, Key Employees
Shionogi & Co Ltd, Key Employee Biographies
Shionogi & Co Ltd, Major Products and Services
Shionogi & Co Ltd, History
Shionogi & Co Ltd, Subsidiaries
Shionogi & Co Ltd, Joint Venture
Shionogi & Co Ltd, Business Unit
Shionogi & Co Ltd, Key Competitors
Shionogi & Co Ltd, Ratios based on current share price
Shionogi & Co Ltd, Annual Ratios
Shionogi & Co Ltd, Annual Ratios (Cont...1)
Shionogi & Co Ltd, Annual Ratios (Cont...2)
Shionogi & Co Ltd, Interim Ratios
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Shionogi & Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Shionogi & Co Ltd, Performance Chart (2020 - 2024)
Shionogi & Co Ltd, Ratio Charts
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings